Obtain long term safet and clinical status information on peds patients with IBD.This report was received from 
clinical trial 
cone a  -year-o emale (subject MI site 
rom he United to es; oval case ID: not reported. 
The subject's height was 131.3 centimeters and weight was 30 kilograms. The subject's concurrent conditions 
included inflammatory bowel disease. The subject was not currently participating in any other registry or clinical 
trial. The subject was treated with infliximab, recombinant (lyophilized powder, intravenous) dose and frequency 
unspecified, initiated on 09-MAR-2011 for inflammatory bowel disease. The subject discontinued infliximab on 15-
DEC-2011 due to poor response and antibodies against infliximab. On 10-FEB-2012; the subject initiated 
adalimumab and was continuing. Concomitant medications included phenoxymethylpenicillin potassium, clonidine, 
procaterol hydrochloride, cetirizine hydrochloride, diphenhydramine hydrochloride, risperidone, adalimumab for 
inflammatory bowel disease, amoxicillin, cefdinir, mesalazine for inflammatory bowel disease, nystatin, fluticasone 
Print Time: 18-JUL-2014 02:07 PM If a field is blank, there is no data for that field Page 306 of 328 
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information 
propionate, and valproate semisodium. On 08-AUG-2013, the subject started with abdominal pain, loose stools and 
decreased appetite. In AUG-2013, the stool analysis for Clostridium difficile was positive. The subject was treated 
with Flagyl (metronidazole) for 10 days and symptoms resolVed..The serious adverse event as severe Clostridium 
difficile infection (bacterial, other gram positive) was not secondary to disease progression, did not result in or 
related to a surgical procedure. Action taken with infliximab, recombinant was not applicable. The subject had 
recovered without sequelae from Clostridium difficile on 19-AUG-2013. The investigator did not provide the 
causality between Clostridium difficile and infliximab, recombinant. The investigator assessed the event as possibly 
related to concomitant medications amoxicillin and cefdinir and not related to concomitant medications 5-ASA 
(oral), nystatin cream, fluticasone propionate, divalproex sodium, penicillin v potassium, clonidine, albuterol sulfate, 
adalimumab, risperidone, cetirizine and diphenhydramine. Company causality was assessed as doubtful. 
This report was serious (medically significant). 
This case, involving the same patient is linked to 20110703742, 26110703908 and 20120402232, 
Additional information was received from the investigator on 27-AUG-2013. 
The dosage form the concomitant medication (fluticasone propionate) was updated as, inhalation. 
Additional information was received from an investigator on 06-SEP-2013. 
The investigator assessed the causality between Clostridium difficile and infliximab, recombinant as not related. 
Company causality was assessed as not related (previously reported as doubtful).